P created Fasudil, a drug which P sought to market in the U.S. for treatment of pulmonary arterial hypertension. P entered into a licensing and development agreement CoTherix, a California-based biopharmaceutical company focused on developing and commercializing products for the treatment of cardiovascular disease. D is a Swiss pharmaceutical company that markets a PAH treatment drug, bosentan (under the trade name Tracleer), and holds the dominant share of the relevant market. D, through a subsidiary, acquired all of the stock of CoTherix, and concurrently notified P that CoTherix would discontinue development of Fasudil for “business and commercial reasons.” P sued Ds for interference with P's prospective economic advantage. The jury returned a unanimous liability verdict against Ds, awarding nearly $546.9 million in compensatory damages, and finding that all Ds acted with malice, oppression or fraud. The jury awarded punitive damages against the Individual Defendants. The trial court denied a motion for new trial on damages, conditioned on P's acceptance of a remittitur of certain damage categories. P accepted the remittitur. Ds appealed.

This section contains the nature of the case and procedural background.

The legal issues presented in this case will be displayed here.

The court's holding and decision will be displayed here.

Legal analysis from Dean's Law Dictionary will be displayed here.